Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Subunit |
Clinical data | |
Trade names | Covovax,[1] Nuvaxovid[2][3][4] |
Other names | |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category | |
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
DrugBank | |
UNII | |
KEGG |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax,[1] among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).[29]
Nuvaxovid EPAR
was invoked but never defined (see the help page).© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search